R&D | May 07, 2026
Lifts full-year outlook as obesity drug boom accelerates
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
Subscribe To Our Newsletter & Stay Updated
